drugset / Trial / NCT06517641
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Phase 2
Recruiting
60 enrolled
Medical College of Wisconsin
National Cancer Institute (NCI) · collabNational Heart, Lung, and Blood Institute (NHLBI) · collabSanofi · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
Timeline
- Start
- 2025-05-12
- Primary completion
- 2028-08-01
- Completion
- 2029-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Comparator | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |
| Comparator | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Comparator | Mycophenolate Mofetil | Small molecule | 15 mg/kg | Oral |
| Comparator | Tacrolimus | Small molecule | — | — |